Platelet Aggregation in the Diagnosis of Acute Graft Rejection

Recruiting now

Conditions studied: Platelet Aggregation, Kidney Transplant Rejection

In brief

The study titled "Platelet Aggregation in the Diagnosis of Acute Graft Rejection" is a pilot observational study evaluating whether alterations in platelet function can serve as non-invasive markers of acute rejection in kidney transplant recipients. Platelet aggregation is assessed using optical aggregometry, flow-cytometric P-selectin (CD62-P) expression, and soluble P-selectin levels before kidney transplantation and at the time of protocol biopsies performed at 3 and 12 months after kidney transplantation. Patients with suspected graft dysfunction undergoing indication biopsy are also included. Platelet activation markers are correlated with histopathological findings, donor-specific antibodies, metabolic parameters, and clinical outcomes. The goal is to determine whether platelet activation profiles can identify acute cellular or antibody-mediated rejection and contribute to the development of a non-invasive diagnostic tool.

Key facts

Study ID

NCT07275541

Run by

University Hospital, Martin

People needed

60

Starts

2024-11-26

Expected to finish

2027-11-26

Last updated by the study team

2025-12-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adult patients (≥18 years)
• primary kidney transplantation
• living / deceased donor kidney transplantation
• ability and consent to participate

You may not qualify if…

• non-adult patients
• secondary / tertiary kidney transplantation
• antiplatelet therapy
• patients unable to provide informed consent

Where it is running

• Transplant-Nephrology Department, University Hospital Martin — Martin, Slovakia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.